Olathe, Kan., Aug. 4, 2015 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ECI-OSA-11, the company’s T cell-based immunotherapy for the treatment of osteosarcoma, a common form of canine cancer for which there is no cure.

This fully-funded clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. The trial will be conducted at the University of Missouri, Columbia College of Veterinary Medicine.

ECI-OSA-11 is a form of immunotherapy that involves treating the patient with its own cancer-specific “killer” T cells. The patient will have surgery to remove their osteosarcoma and then will be treated with ECI-OSA-11 to eliminate cancer cells that remain following surgery.

The objective of this clinical trial is to determine whether ECI-OSA-11 could replace chemotherapy as the standard treatment for canine osteosarcoma. Efficacy will be determined by comparing the outcomes obtained with surgery plus ECI-OSA-11 to the outcomes obtained with surgery plus chemotherapy.

“According to the National Canine Cancer Foundation, osteosarcoma is the most common bone cancer in dogs with as many as 10,000 new cases diagnosed in the country every year,” said Tammie Wahaus, chief executive officer, ELIAS Animal Health. “ECI-OSA-11 represents a truly unique approach to treating canine osteosarcoma. We look forward to reporting the results of this trial.”

Media contact:
Ted Glickman
Stephens & Associates Advertising

Veterinarians interested in more information on the clinical program, please visit www.eliasanimalhealth.com or contact ELIAS at clinicaltrials@eliasah.com. Interested investors may contact info@eliasah.com.

About ELIAS Animal Health
Based in Olathe, Kan., ELIAS Animal Health is a medical biotechnology company advancing its novel targeted T cell-based immunotherapies for the treatment of canine cancers. The ELIAS cancer immunotherapy is being distributed to veterinarians under 9 CFR 103.3 as an experimental product. The company’s novel therapeutic approach offers the promise of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. For more information, please visit www.eliasanimalhealth.com.